These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

976 related items for PubMed ID: 25211402

  • 1. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
    Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, Shioura T, Saito K, Hirano Y, Kanayama Y, Miyake H, Asai N, Funahashi K, Hirabara S, Hanabayashi M, Asai S, Ishiguro N.
    Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
    [Abstract] [Full Text] [Related]

  • 2. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [Abstract] [Full Text] [Related]

  • 3. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
    Sugiyama N, Kawahito Y, Fujii T, Atsumi T, Murata T, Morishima Y, Fukuma Y.
    Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
    [Abstract] [Full Text] [Related]

  • 4. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
    Sato E, Tanaka E, Ochiai M, Shimizu Y, Kobayashi A, Shidara K, Hoshi D, Sugimoto N, Inoue E, Seto Y, Nakajima A, Taniguchi A, Momohara S, Yamanaka H.
    Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
    [Abstract] [Full Text] [Related]

  • 5. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
    Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, Hara R, Katayama M, Yoshida S, Nagai K, Son Y, Amuro H, Akashi K, Fujimura T, Hirao M, Yamamoto K, Shintani A, Kumanogoh A, Yoshikawa H.
    PLoS One; 2018 May; 13(3):e0194130. PubMed ID: 29543846
    [Abstract] [Full Text] [Related]

  • 6. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L, Taylor M, Soonasra A, Bourret JA, Gerber RA.
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [Abstract] [Full Text] [Related]

  • 7. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
    Lequerré T, Farran É, Ménard JF, Kozyreff-Meurice M, Vandhuick T, Tharasse C, Pouplin S, Daragon A, Le Loët X, Varin R, Vittecoq O.
    Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
    [Abstract] [Full Text] [Related]

  • 8. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
    Kihara M, Davies R, Kearsley-Fleet L, Watson KD, Lunt M, Symmons DP, Hyrich KL, British Society for Rheumatology Biologics Register.
    Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
    [Abstract] [Full Text] [Related]

  • 9. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.
    Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K, Kunugiza Y, Shi K, Narazaki M, Hagihara K, Tomita T, Yoshikawa H, Tanaka T, Kumanogoh A.
    Scand J Rheumatol; 2013 Feb; 42(4):253-9. PubMed ID: 23470089
    [Abstract] [Full Text] [Related]

  • 10. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
    Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Harrison DJ, Joseph GJ, Sauer BC.
    J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516
    [Abstract] [Full Text] [Related]

  • 11. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
    Soubrier M, Pereira B, Frayssac T, Fan A, Couderc M, Malochet-Guinamand S, Mathieu S, Tatar Z, Tournadre A, Dubost JJ.
    Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
    [Abstract] [Full Text] [Related]

  • 12. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
    Matsubara H, Kojima T, Kaneko A, Hirano Y, Ishikawa H, Hattori Y, Miyake H, Oguchi T, Takagi H, Yabe Y, Kato T, Ito T, Fukaya N, Kanayama Y, Shioura T, Hayashi M, Fujibayashi T, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Terabe K, Ishiguro N.
    J Rheumatol; 2014 Aug; 41(8):1583-9. PubMed ID: 25028370
    [Abstract] [Full Text] [Related]

  • 13. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R, Bazzani C, Atzeni F, Sarzi Puttini PC, Fusaro E, Pellerito R, Caporali R.
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [Abstract] [Full Text] [Related]

  • 14. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
    Favalli EG, Biggioggero M, Marchesoni A, Meroni PL.
    Rheumatology (Oxford); 2014 Sep; 53(9):1664-8. PubMed ID: 24729445
    [Abstract] [Full Text] [Related]

  • 15. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL.
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [Abstract] [Full Text] [Related]

  • 16. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
    Soubrier M, Pereira B, Fan A, Frayssac T, Couderc M, Malochet-Guinamand S, Mathieu S, Tatar Z, Tournadre A, Dubost JJ.
    Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265
    [Abstract] [Full Text] [Related]

  • 17. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
    Shimizu Y, Tanaka E, Inoue E, Shidara K, Sugimoto N, Seto Y, Nakajima A, Momohara S, Taniguchi A, Yamanaka H.
    Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
    [Abstract] [Full Text] [Related]

  • 18. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
    Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H.
    Arthritis Res Ther; 2019 Apr 11; 21(1):91. PubMed ID: 30971306
    [Abstract] [Full Text] [Related]

  • 19. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D, Tavares-Costa J, Eusébio M, Leite Silva J, Ramos Rodrigues J, Sousa-Neves J, Duarte AC, Lopes C, Valido A, Dinis J, Freitas J, Santiago M, Ferreira R, Ganhão S, Miranda L, Peixoto D, Teixeira F, Alcino S, Afonso C, Santos MJ.
    Acta Reumatol Port; 2019 Apr 11; 44(2):103-113. PubMed ID: 31243259
    [Abstract] [Full Text] [Related]

  • 20. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.
    Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewé R, Smolen JS, Emery P, Buch MH.
    Ann Rheum Dis; 2010 Jun 11; 69(6):976-86. PubMed ID: 20447957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.